Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors while in the central anxious system, conolidine modulates alternate molecular targets. A Science Advancements research found that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid https://cheq580una0.wikidirective.com/user